| Endometrial Carcinoma

Imfinzi vs Jemperli

Side-by-side clinical, coverage, and cost comparison for endometrial carcinoma.

Deep comparison between: Imfinzi vs Jemperli with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsJemperli has a higher rate of injection site reactions vs Imfinzi based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Jemperli but not Imfinzi, including UnitedHealthcare

Category

Imfinzi

Jemperli

At A Glance

RouteIV infusion

FrequencyEvery 2 to 4 weeks

ClassPD-L1 antagonist

RouteIV infusion

FrequencyEvery 3-6 weeks

ClassPD-1 inhibitor

Indications

Non-Small Cell Lung Carcinoma
Small cell carcinoma of lung
Biliary Tract Cancer
Liver carcinoma
Endometrial Carcinoma
Carcinoma of bladder
Stomach Carcinoma
Gastroesophageal junction cancer

Endometrial Carcinoma
Solid Neoplasm

Dosing

Resectable NSCLC Neoadjuvant: 1,500 mg IV every 3 weeks in combination with chemotherapy for up to 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 12 cycles after surgery (or 20 mg/kg if weight <30 kg).

Unresectable Stage III NSCLC 1,500 mg IV every 4 weeks or 10 mg/kg every 2 weeks as a single agent until disease progression or unacceptable toxicity (maximum 12 months) (or 10 mg/kg every 2 weeks if weight <30 kg).

Metastatic NSCLC 1,500 mg IV in combination with tremelimumab-actl 75 mg and platinum-based chemotherapy every 3 weeks for 4 cycles, then 1,500 mg every 4 weeks as a single agent with pemetrexed maintenance for non-squamous (or 20 mg/kg and 1 mg/kg tremelimumab-actl if weight <30 kg).

Limited Stage SCLC 1,500 mg IV every 4 weeks as a single agent until disease progression or unacceptable toxicity (maximum 24 months) (or 20 mg/kg if weight <30 kg).

Extensive Stage SCLC 1,500 mg IV every 3 weeks in combination with etoposide and carboplatin or cisplatin for 4 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).

Biliary Tract Cancer 1,500 mg IV every 3 weeks in combination with gemcitabine and cisplatin for up to 8 cycles, then 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg if weight <30 kg).

Unresectable Hepatocellular Carcinoma 1,500 mg IV in combination with a single dose of tremelimumab-actl 300 mg at Cycle 1/Day 1, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 20 mg/kg and 4 mg/kg tremelimumab-actl if weight <30 kg).

dMMR Endometrial Carcinoma 1,120 mg IV in combination with carboplatin and paclitaxel every 3 weeks for 6 cycles, followed by 1,500 mg every 4 weeks as a single agent until disease progression (or 15 mg/kg followed by 20 mg/kg if weight <30 kg).

Muscle Invasive Bladder Cancer Neoadjuvant: 1,500 mg IV in combination with gemcitabine and cisplatin every 3 weeks for 4 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks as a single agent for up to 8 cycles after surgery (or 20 mg/kg if weight <30 kg).

Resectable Gastric/Gastroesophageal Junction Adenocarcinoma Neoadjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles prior to surgery (or 20 mg/kg if weight <30 kg). Adjuvant: 1,500 mg IV every 4 weeks with FLOT for up to 2 cycles, followed by 1,500 mg as a single agent every 4 weeks for up to 10 cycles (or 20 mg/kg if weight <30 kg).

Endometrial Carcinoma 500 mg IV every 3 weeks for 6 cycles with carboplatin and paclitaxel, followed by 1,000 mg IV monotherapy every 6 weeks; administer prior to carboplatin and paclitaxel when given on the same day.

Endometrial Carcinoma, Solid Neoplasm 500 mg IV every 3 weeks for 4 cycles followed by 1,000 mg IV every 6 weeks as monotherapy; for dMMR-selected patients only.

Contraindications

—

Drug Interactions

203View drug interactions

189View drug interactions

Adverse Reactions

Most common (>=10%) Nausea, fatigue, cough, pneumonitis, rash, diarrhea, decreased appetite, musculoskeletal pain, constipation, dyspnea, upper respiratory tract infections, pyrexia, pruritus, headache, vomiting, abdominal pain, hypothyroidism, peripheral neuropathy, alopecia, insomnia

Serious Pneumonitis, pneumonia, hepatitis, colitis, myocarditis, nephritis, endocrinopathies, infusion-related reactions, exfoliative dermatologic conditions

Postmarketing Not specified in label

Most common (>=20%) Fatigue, nausea, diarrhea, constipation, vomiting, anemia, peripheral neuropathy, alopecia, rash, arthralgia, abdominal pain, dyspnea, decreased appetite, urinary tract infection

Serious Sepsis (including urosepsis), pulmonary embolism, urinary tract infection, acute kidney injury, abdominal pain

Pharmacology

Durvalumab is a human IgG1 kappa monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, releasing the inhibition of immune responses without inducing antibody-dependent cell-mediated cytotoxicity.

Dostarlimab-gxly is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Imfinzi